BB BIOTECH overview

EQS-News: BB BIOTECH AG / Key word(s): AGM/EGM/Dividend Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share 21.03.2024 / 18:00 CET/CEST The issuer is solely responsible for the content of this announcement. Media release of March 21, 2024 Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech...

EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Annual Report/Dividend BB Biotech AG publishes its 2023 annual report 16-Feb-2024 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR February 16, 2024 Annual report of BB Biotech AG as at December 31, 2023 BB Biotech AG publishes...

EQS-News: BB BIOTECH AG / Key word(s): Dividend Investor interest returns – dividend yield remains high for 2024 14.02.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Release as at February 14, 2024 Investor interest returns – dividend yield remains high for 2024 After a difficult 2023 stock market year, above all due to higher interest rates, the capital markets are now once again looking at biotech companies with interest. The prospect of...

EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Annual Results/Personnel BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors 19-Jan-2024 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR January 19, 2024 BB Biotech AG publishes financial...

EQS-News: BB BIOTECH AG / Key word(s): Annual Results/Dividend BB Biotech AG: End of year biotech equity market rally – M&A and end of rate hike cycle 19.01.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Media release as at January 19, 2024 Portfolio of BB Biotech AG as at December 31, 2023 End of year biotech equity market rally – M&A and end of rate hike cycle In 2023, global equity performed better than anticipated by many. The US central bank...

EQS-News: BB BIOTECH AG / Key word(s): Interim Report BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies 20.10.2023 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Media release as at October 20, 2023 Interim report of BB Biotech AG as at September 30, 2023 Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies Expectations that the US central bank...

EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report BB Biotech AG publishes its interim report 20-Oct-2023 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR October 20, 2023 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published...

EQS-News: BB BIOTECH AG / Key word(s): Interim Report BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry 21.07.2023 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Media release as at July 21, 2023 Interim report of BB Biotech AG as at June 30, 2023 Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen...